Drug Profile
Research programme: T-cell specific antibody therapies - Medigene AG
Alternative Names: TABs - Medigene AGLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Trianta Immunotherapies
- Developer MediGene AG
- Class Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; T-cell leukaemia
Most Recent Events
- 28 Mar 2023 Discontinued - Preclinical for Autoimmune disorders in Germany (Parenteral) (Medigene pipeline, March 2023)
- 28 Mar 2023 Discontinued - Preclinical for T-cell leukaemia in Germany (Parenteral) (Medigene pipeline, March 2023)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Autoimmune-disorders in Germany (Parenteral)